+91 80 2808 2808

Biocon Foundation Celebrates the Spirit of ‘Har Ghar Tiranga’

  • Posted by: BIOCON
Distributes Tricolour Among Children of 60 govt schools, Communities from 15 villages, and Biocon Group’s staff

Bengaluru, Karnataka, India, August 13, 2022

The Biocon Group announced its support for the nationwide ‘Har Ghar Tiranga’ campaign launched during the week through its CSR arm, Biocon Foundation. Over 30,000 national flags were distributed amongst the communities living in the vicinity of its offices in and around Electronic City, Bangalore. Through this initiative Biocon Group of Companies including Biocon Limited, Biocon Biologics Limited and Syngene International Limited are participating  in the ‘Azadi Ka Amrit Mahotsav’ of the Government of India to mark 75th year of India’s Independence.

Biocon Foundation, which is the principal channel for Biocon Group’s corporate philanthropy to build sustainable solutions that promote social and economic inclusion, distributed the Tricolor among members of the local communities, anganwadi workers, students and teachers in government schools in three Panchayats of Anekal taluk.

The flags were distributed by the Foundation among students from 60 schools, residents of 15 villages across locations in Electronic City, Huskur and Jigani Industrial areas in the neighbourhood of Biocon Group companies’ campuses, through Panchayats and Village representatives. Many employees of the three companies: Biocon, Biocon Biologics and Syngene are also participating in ‘Har Ghar Tiranga’ initiative and proudly displaying the national flag at their homes.

The Foundation, in collaboration with the panchayats of Huskur (7 villages), Hennagara (8 villages), and municipal bodies like Hebbagodi, organized several events to hand over the national flags for the communities, thus enabling everyone to participate in the nationwide ‘Har Ghar Tiranga’ Campaign and proudly  display the Tricolor in their homes from August 13 to August 15, 2022 as part of the nationwide ‘75th Azadi Ka Mahotsav’.  The Foundation has also provided the ‘Flag Code of India’ to the community member and urged them to comply with the code in letter & spirit.

The events saw the participation of dignitaries such as Ms Shwetha Bai, CMC Commissioner, Hebbagodi, Panchayat Head Mrs Muniratna Muniraju,  Hennagara  Panchayata , Members, Development Officers, School Principals, Village representatives, as well as residents of the surrounding villages.

Wishing every Indian on the occasion, Dr Kiran Mazumdar-Shaw, Managing Trustee of Biocon Foundation, said,  “The 75th anniversary of India’s Independence is a proud milestone for a nation aspiring for global leadership. As we celebrate Azadi Ka Amrit Mahotsav, I believe the national flag best represents our flourishing democracy, our innovative and inclusive economy, and our ability to drive transformative change. Over the years, countless Indians including members of our armed forces have bravely and unquestioningly laid down their lives to keep the tricolour flying in its full glory. As proud citizens of Independent India, it  is our duty to honour their sacrifices by making India the greatest nation in the world.  

“This is the belief that made us bring communities together by being a part of the ‘Har Ghar Tiranga’ campaign of the Government of India. Taking this initiative forward, we are distributing thousands of flags among the local communities, schoolchildren as well as employees of the Biocon Group to inspire them to give their best for the greater glory of our nation.”

Hebbagodi CMC Commissioner Shwetha Bai, said, “We have worked with Biocon Foundation on several projects, including the rejuvenation of the Hebbagodi Lake. The rejuvenated lake now meets the needs of the people living in and around the lake. This initiative builds a sense of duty among the people towards preserving and conserving our country’s natural resources.”

Dr Anupama Narayan Shetty, Mission Director, Biocon Foundation, said, “Biocon Foundation is proud to be a part of the Har Ghar Tiranga campaign to mark India’s 75th Independence Day, and have distributed the national flag among households in Huskur, Hebbagodi, Hennagara and Yarandahalli to encourage the common man to proudly display the tricolour at home. We are happy that we are able to promote awareness about our national flag with the communities with whom we have been working over the years through various initiatives aimed at ensuring better healthcare and education, environmental management and ecological conservation.

Senior management of the three Biocon Group companies has extended their full support to this initiative. Some of the members attending the community outreach were Mr Mukesh Kamath , Associate Vice President, Finance  Biocon,  Mr Susheel Umesh, Chief Commercial Officer, Biocon Biologics, Ms Seema Ahuja, Global Head of Communications, Biocon Biologics, Mr Kenneth Barr – Senior VP, Discovery Services, Syngene, Mr Rajendra Patil, Sr General Manager, EHS, Syngene, Mr Ravi Kumar, Head, EHS, Biocon, Sunil Koteel, General Manger, Administration, Biocon were also present.

The Government of India recently announced the ‘Har Ghar Tiranga’ Campaign as a part of the Azadi ka Amrit Mahotsav, which celebrates the 75th anniversary of Independence Day. As part of this campaign, Prime Minister Narendra Modi has urged all Indians to fly the national flag at their homes between August 13 and August 15, 2022. To aid this, the government has authorized the use of polyester and equipment for flag production. The previous law permitted hand-spun and hand-woven flags constructed of khadi, cotton, wool, silk and bunting material.

About Biocon Foundation:

Biocon Foundation, the Corporate Social Responsibility arm of Biocon and Syngene International, is working to empower marginalized communities since 2005. Biocon Foundation partners with the society to promote social and economic inclusion. It has thus made significant investments in enhancing access to quality healthcare, education and civic infrastructure along with environmental sustainability projects. Combined with field initiatives, these programs create a momentum to elevate the marginalized sections of the society. Over the years, Biocon Foundation has built a strong reputation for the quality of its programs and their impact in addressing the social, humanitarian and environmental challenges facing India. To make a more meaningful impact, the Foundation regularly partners with government agencies and like-minded organizations for program delivery. Besides addressing critical national and state level challenges in primary healthcare, education and rural development, the Foundation is also augmenting  environmental sustainability through the lake revival mission in Bengaluru. Visit:

About Biocon Ltd.:

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. Website:; Follow-us on Twitter: @bioconlimited for company updates.

About Biocon Biologics Ltd:

Biocon Biologics Ltd., a subsidiary of Biocon Ltd., is a unique, fully-integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower costs of biologics therapies while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology and other non-communicable diseases. Seven molecules from Biocon Biologics’ portfolio have been commercialized in key emerging markets and developed markets like U.S., EU, Australia, Canada, Japan. It has many firsts to its credit including the most recent U.S. FDA approval of the world’s first interchangeable biosimilar, awarded to its Insulin Glargine, which has been commercialized in the U.S. in 2021. Biocon Biologics has signed a strategic alliance with Serum Institute Life Sciences (subject to certain closing conditions) to address the inequitable access to life saving vaccines and biologics globally. With a team of ~5,000 people, Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to millions of patients’ worldwide.

About Syngene International Ltd:

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Syngene’s more than 5200 scientists offer both skills and the capacity to deliver great science, robust data management and IP security and quality manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter and Bristol-Myers Squibb as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA. For more details, visit

Author: BIOCON
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>